Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer.

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...

Eli Lilly (LLY) said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash.

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating yesterday.Stay Ahead of the ...